Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cue Biopharma, Inc. filings document material events, governance actions, operating results, and capital-structure matters for a clinical-stage biopharmaceutical company focused on immune-modulating biologics. The company's 8-K reports cover executive transitions, collaboration milestones, financial results, registered common stock matters, and amendments related to a reverse stock split.
Proxy and meeting-related filings describe director elections, auditor ratification, executive compensation votes, stockholder proposal procedures, and amendments to governing documents. Other disclosures address research and development programs including CUE-401, CUE-501, the Immuno-STAT platform, collaboration and license agreements, equity compensation arrangements, and risk factors associated with clinical-stage biotechnology operations.
Garzone Pamela reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that director Pamela Garzone received a grant of 21,800 shares of Common Stock in the form of restricted stock units. One-third of the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, contingent on her continued service with the company. Following this equity award, she holds 21,800 shares directly.
Camardo Daniel A. reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that director Daniel A. Camardo received a grant of 21,800 shares of Common Stock in the form of restricted stock units. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to his continued service with the company. Following this award, he holds 21,800 shares of Common Stock directly.
Sarraf Pasha reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. director Sarraf Pasha received a grant of 21,800 restricted stock units (RSUs) of common stock. One-third of these RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service. Following this award, Pasha holds 32,595 shares (on a post–1-for-30 reverse split basis effective April 22, 2026).
Meehan Viola Mong reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. director Meehan Viola Mong received an equity compensation award of 21,800 shares of Common Stock in the form of restricted stock units. The RSUs were granted at a stated price of $0.00 per share and are held directly. One-third of the shares underlying the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to continued service with the company through each vesting date. Following this award, the reporting person holds 21,800 shares of Common Stock.
Cue Biopharma, Inc. reported an equity compensation grant to officer Michael Vincent Meluzio, VP and Principal Accounting Officer. He received 40,942 shares of common stock through restricted stock units that vest in equal quarterly installments over 48 months from the grant date, conditioned on continued service. He also received a separate grant of 40,942 performance stock units that may convert into common shares only if the stock trades at or above $33.00, $38.50, and $44.00 for five consecutive trading days for each tranche within 24 months, after which any unmet tranches are forfeited.
Ray Sumita reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. granted Chief Legal Compliance Officer and Corporate Secretary Sumita Ray a total of 109,178 shares tied to equity awards on July 9, 2026. The awards comprise 54,589 restricted stock units (RSUs) vesting in equal quarterly installments over 48 months and 54,589 performance stock units (PSUs) that vest in three tranches only if stock-price targets of $33.00, $38.50 and $44.00 are each maintained for five consecutive trading days by 24 months from grant, otherwise the PSUs are forfeited.
Lin Shao-Lee reported acquisition or exercise transactions in this Form 4 filing.
Cue Biopharma, Inc. reported that Chief Executive Officer Shao-Lee Lin received equity awards covering 327,537 shares of Common Stock on July 9, 2026. The awards consist of restricted stock units and performance stock units, and Lin now holds 655,074 Common shares directly following these grants.
Cue Biopharma, Inc. entered into a private placement with accredited investors, including Cormorant Asset Management and Columbia Threadneedle Investments, to raise gross proceeds of approximately $50.0 million. The transaction covers 1,418,071 shares of common stock at $33.21 per share and pre-funded warrants to purchase up to 87,500 shares at $33.209 per warrant.
The pre-funded warrants are immediately exercisable at $0.001 per share on a cashless basis and include beneficial ownership limits of 4.99% or 9.99%, which can increase up to 19.99% with notice. Cue plans to use net proceeds to fund clinical development and for general corporate purposes. The closing is expected on July 13, 2026, subject to customary conditions, and the company agreed to register the resale of the securities within 30 days of closing.
Separately, under its 2026 Stock Incentive Plan, Cue granted 1,064,492 RSUs to employees and executives, including 655,074 RSUs to CEO Shao‑Lee Lin, 109,178 to the Chief Legal and Compliance Officer, and 81,884 to the Principal Accounting Officer, plus 21,800 RSUs to each non‑employee director.
Cue Biopharma, Inc. registers 551,724 shares of common stock for resale by Ascendant Health Sciences, Ltd. These 551,724 shares are issuable upon exercise of pre-funded warrants and are being registered for resale by the selling stockholder; the company will not receive proceeds from those resale transactions except nominal proceeds equal to the $0.001 cash exercise price per share for any Pre-Funded Warrants exercised for cash. The Pre-Funded Warrants were issued as partial consideration under a Securities Purchase Agreement dated April 30, 2026. As context, shares outstanding were 4,200,343 as of June 1, 2026, and the last reported sale price on June 17, 2026 was $26.73 per share.